ALLMedicine Plaque Psoriasis Center

Jun 1st, 2020 - Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first...

Jun 1st, 2020 - Aims: To estimate cost per response (CPR) in the United States and number-needed-to-treat (NNT) among subjects receiving guselkumab or secukinumab for moderate to severe plaque psoriasis.Materials and methods: Results from ECLIPSE, a double-blind,...

May 31st, 2020 - Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. To provide longer-term efficacy and safety data for bimek...

May 26th, 2020 - Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.|2020|Pagnini C,Di Paolo MC,De Angelis G,Torcolacci F,Milano M,|

May 25th, 2020 - The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA. Integrated safety data from 21 clinical trials are presented by indication in patients who received...

Feb 29th, 2020 - Psoriasis is a chronic inflammatory skin disease characterized by scaly indurated erythema. It impairs patients’ quality of life enormously. It has been recognized not only as a skin disease but as a systemic disease, since it also causes arthriti...

Feb 24th, 2020 - Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascul...

Feb 4th, 2020 - In a network meta-analysis of 60 clinical trials for short-term efficacy, brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa had the highest Psoriasis Area and Severity Index response rates at 10 to 16 weeks from baseline. A meta-analysis o...

Jan 8th, 2020 - Psoriasis is an immune‐mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is cur...

Nov 30th, 2019 - Plaque psoriasis is a chronic, immune-mediated disease, which has a multifactorial etiopathogenesis. Practical non-invasive techniques to monitor plaque psoriasis progression and treatment are necessary. Imaging techniques available for psoriasis ...

Jun 1st, 2020 - Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first...

Jun 1st, 2020 - Aims: To estimate cost per response (CPR) in the United States and number-needed-to-treat (NNT) among subjects receiving guselkumab or secukinumab for moderate to severe plaque psoriasis.Materials and methods: Results from ECLIPSE, a double-blind,...

May 31st, 2020 - Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone. To provide longer-term efficacy and safety data for bimek...

May 31st, 2020 - The Food and Drug Administration has extended approval of ixekizumab (Taltz) to the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), according to a press release from its manufacturer, Eli Lilly. Specifically, this supplemental bio...

May 26th, 2020 - Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.|2020|Pagnini C,Di Paolo MC,De Angelis G,Torcolacci F,Milano M,|

May 31st, 2020 - The Food and Drug Administration has extended approval of ixekizumab (Taltz) to the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), according to a press release from its manufacturer, Eli Lilly. Specifically, this supplemental bio...

May 20th, 2020 - Approximately 125 million people around the world are affected by psoriasis, a chronic, relapsing inflammatory skin disorder. Several clinical variants of psoriasis are recognized, but plaque psoriasis is the most common. Psoriasis is associated w...

May 20th, 2020 - Plaque psoriasis is a chronic inflammatory disease that primarily affects the skin and joints. Globally, approximately 125 million people have psoriasis. Certain medications, infections, skin trauma, obesity, and stress have been recognized as dis...

Mar 30th, 2020 - The Food and Drug Administration has approved ixekizumab for treatment of moderate to severe plaque psoriasis in patients aged 6-17 years, according to an announcement from Lilly. Patients need to be candidates for systemic therapy or phototherapy.

Mar 11th, 2020 - To the Editor: The incidence of psoriasis in human immunodeficiency virus (HIV)–infected patients is similar to the general population, but it usually becomes more severe as immunosuppression increases. Additionally, it tends to be more resistant.